From Name:
From Email:
To Name:
To Email:

Optional Message:

Bayer wins FDA approval for a long-acting hemophilia drug

from FierceBiotech

Bayer won FDA approval for a twice-a-week therapy for hemophilia A, wading into a crowded field of drugmakers angling to launch more convenient treatments for the disease. The agency signed off on Kovaltry, a treatment that can be dosed two or three times a week in adults and every other day in children. Like Bayer's blockbuster daily treatment Kogenate, the new injection treats hemophilia A by replacing a key coagulation protein called factor VIII, helping patients' blood to clot normally and reducing the dangerous bleeds that characterize the disease. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063